Wall Street Zen Upgrades Vanda Pharmaceuticals (NASDAQ:VNDA) to “Sell”

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

Several other research analysts also recently commented on VNDA. B. Riley Financial reissued a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Zacks Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Oppenheimer started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Monday, October 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.50.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock opened at $3.79 on Friday. The stock’s 50-day moving average price is $4.79 and its 200-day moving average price is $6.22. Vanda Pharmaceuticals has a 12-month low of $3.74 and a 12-month high of $9.94. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $229.18 million, a price-to-earnings ratio of -0.82 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. The business had revenue of $69.81 million for the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. Equities research analysts predict that Vanda Pharmaceuticals will post -2.68 EPS for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC boosted its stake in Vanda Pharmaceuticals by 8.8% during the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 3,144 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at $29,000. Legal & General Group Plc bought a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $34,000. Allworth Financial LP bought a new stake in Vanda Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, SG Americas Securities LLC lifted its holdings in Vanda Pharmaceuticals by 94.7% in the first quarter. SG Americas Securities LLC now owns 21,042 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 10,235 shares during the period. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.